A
Alcista
Alcista · 25%JAGX
$5.29
Precio del escenario
$0.433
+0.032 (+7.34%)Al cierre
Loading chart…
- Máximo
- 0.450
- Apertura
- 0.388
- Precio medio ponderado por volumen
- 0.42
- Volumen
- 884.55K
- Capitalización
- 17.70M
- Mínimo
- 0.363
- Importe
- 367.30K
- EV/EBITDA, TTM
- -0.18
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Análisis de IA of Jaguar Health Inc (JAGX)
VenderJaguar Health Inc (JAGX) is not a good buy right now. The stock has experienced a staggering 99.92% decline year-to-date and a 75.10% drop over the last five days, indicating severe downward momentum. Additionally, the RSI is at a very low 13.443, suggesting the stock is oversold but may continue to face selling pressure. The forward P/E ratio is extremely high at 200, reflecting uncertainty about future earnings and growth potential. The main risk is the company's negative net income, which was -12,701,000 USD in Q2 2026, indicating ongoing financial challenges that could hinder recovery.
Recomendaciones de analistas (1)
Comprar
1 Comprar
0 Mantener
0 Vender
Actual: 0.43
Mínimo
—
Promedio
—
Máximo
—
Métricas de valoración
El PER previsto actual de Jaguar Health Inc (JAGX) es 200.00, frente a su media de 5 años de 24.66.
Escenarios de precio de Alphio AI para JAGX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.509-23stocktwitsJAGX Shares Surge Following FDA Fee Waivers and Reverse Split
8.509-22NewsfilterJaguar Health Secures FDA Fee Waiver for Mytesi and Canalevia
8.508-20Yahoo FinanceJaguar Health Secures $18M Deal with FuturePak
- 9.508-18Newsfilter
Jaguar Health to Release Q2 2026 Earnings Report and Host Webcast
1.006-26GlobenewswireVirtual Investor Conferences Forum Highlights
Preguntas frecuentes sobre JAGX, respondidas por Alphio AI
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Jaguar Health Inc (JAGX) is not a good buy right now. The stock has experienced a staggering 99.92% decline year-to-date and a 75.10% drop over the last five days, indicating severe downward momentum. Additionally, the RSI is at a very low 13.443, suggesting the stock is oversold but may continue to face selling pressure. The forward P/E ratio is extremely high at 200, reflecting uncertainty about future earnings and growth potential. The main risk is the company's negative net income, which was -12,701,000 USD in Q2 2026, indicating ongoing financial challenges that could hinder recovery.
1 analysts cover JAGX: 1 rate it Buy, 0 Hold and 0 Sell.
Comunidad
Más ↗
$GNPX has the same share structure as $JAGX with just 820K shares float and $15 per share of net cash. Keep an eye on it. Low float names are hot.
Mostrar másArtículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.